Welcome to CSNpharm! For Research Use Only!
E1/E2/E3 Enzyme
| Cat. No. | Product Name | CAS No. | Information |
|---|---|---|---|
| CSN27721 | CRBN modulator-1 | 2407829-65-4 | WUN29654 is a CRBN modulator with CRBN modulatory activity with IC50 value of 2.6μM, Ki value of 0.7μM and cell proliferation IC50 value of ~21.53μM. |
| CSN23792 | VL285 | 1448188-57-5 | VL285 is a potent VHL ligand, degrading HaloTag7 fusion proteins. |
| CSN22266 | Thalidomide-O-amido-PEG4-C2-NH2 | 1957236-22-4 | Thalidomide-O-amido-PEG4-C2-Amine is a PROTAC block consist of Thalidomide and a linker with Amine functional group for conjugation reactions. |
| CSN22269 | Thalidomide-O-amido-PEG3-C2-NH2 | 1957236-20-2 | Thalidomide-O-amido-PEG3-C2-Amine is a PROTAC block consist of Thalidomide and a linker with an Amine functional group for conjugation reactions. |
| CSN22270 | Thalidomide-O-amido-PEG2-C2-NH2 | 1957235-74-3 | Thalidomide-O-amido-PEG2-C2-Amine is a PROTAC block consist of Thalidomide and a linker with Amine functional group for conjugation reactions. |
| CSN22271 | Thalidomide-O-amido-PEG-C2-NH2 | 2022182-59-6 | Thalidomide-O-amido-PEG-C2-Amine is a PROTAC block consist of Thalidomide and a linker with Amine functional group for conjugation reactions. |
| CSN22274 | Thalidomide-O-amido-C4-NH2 | 1799711-24-2 | Thalidomide-O-amido-C4-Amine is a PROTAC block consist of Thalidomide linked to alkyl with Amine functional group for conjugation reactions. |
| CSN22272 | Thalidomide-O-amido-C3-NH2 | 2022182-57-4 | Thalidomide-O-amido-C3-Amine is a PROTAC block consist of Thalidomide linked to alkyl with Amine functional group for conjugation reactions. |
| CSN28415 | Thalidomide-NH-C4-NH-Boc | 2093388-52-2 | Thalidomide-NH-C4-NH-Boc is a PROTAC block consist of Thalidomide with a Boc functional group for conjugation reactions. |
| CSN22519 | Teslexivir | 1075798-37-6 | Teslexivir is a topical antiviral agent that is a potent and selective inhibitor of the interaction between two essential viral proteins E1 and E2 an interaction that is a necessary step for Human Papilloma Virus HPV 6 and 11 DNA replication and thus viral production |
| CSN21424 | Thalidomide-O-COOH | 1061605-21-7 | TC E3 5031 is a thalidomide derivate for conjugation reactions of PROTAC, which can hijack cereblon as the E3 ubiquitin ligase component. |
| CSN24144 | Subasumstat | 1858276-04-6 | TAK-981 is a first in class and selective inhibitor of the SUMOylation enzymatic cascade, with potential immune-activating and antineoplastic activities. |
| CSN21083 | TAK-243 | 1450833-55-2 | TAK-243, also known as MLN7243 and AOB87172, is a small molecule inhibitor of ubiquitin-activating enzyme (UAE), with potential antineoplastic activity. |
| CSN24085 | Smurf1-IN-A01 | 1007647-73-5 | Smurf1-IN-A01 is an inhibitor of negatively regulatory factor Smurf1 for promoting bone formation. |
| CSN25714 | SMER3 | 67200-34-4 | SMER 3 is a selective inhibitor of yeast SCF family E3 ubiquitin ligase (SCFMet30) in vitro and in vivo. |
| CSN18272 | Skp2 Inhibitor C1 | 432001-69-9 | Skp2 inhibitor C1 is a specific small molecule inhibitor of Skp2-mediated p27 degradation, selectively inhibited Skp2-mediated p27 degradation by reducing p27 binding through key compound-receptor contacts. |
| CSN15975 | PYR-41 | 418805-02-4 | PYR-41 (50 μM) inhibits activity of ubiquitin-activating enzyme E1 by over 90%. |
| CSN22492 | Boc-C1-PEG2-C4-Cl | 1835705-53-7 | PROTAC Linker 1 is a linker used to link the warhead and the E3 ligase ligand. |
| CSN23937 | PROTAC BRD9 Degrader-1 | 2097971-01-0 | PROTAC BRD9 Degrader-1 is a PROTAC targeting on BRD9, consist of a BRD9 bromodomain probe I-BRD9 as a warhead ligand and pomalidomide as the CRBN ligand. |
| CSN19741 | PK 11195 | 85532-75-8 | PK11195 is a 2Phenylindolylglyoxylyldipeptide Murine Double Minute2 MDM2Translocator Protein TSPOHuman Constitutive Androstane Receptor hCAR Inhibitor and is potentially useful for the Treatment of Gliomas |
| CSN25713 | N106 | 862974-25-2 | N106 is an activator of SUMO-activating enzyme E1 ligase. It can increase SERCA2a SUMOylation and activity and enhance contractility in rat cardiomyocytes in vitro. |
| CSN20617 | ML-792 | 1644342-14-2 | ML-792 is a mechanism-based SUMO-activating enzyme SAE inhibitor with nanomolar potency in cellular assays which selectively blocks SAE enzyme activity and total SUMOylation thus decreasing cancer cell proliferation |
| CSN27723 | MID-1 | 312608-54-1 | MID-1 is a MG53-IRS-1 interaction disruptor. It abolished MG53-mediated IRS-1 ubiquitination and degradation, as well as sensitized insulin signaling and increased insulin-elicited glucose uptake with an elevated level of IRS-1 in C2C12 myotubes. |
| CSN20357 | (S,R,S)-AHPC | 1448297-52-6 | MDK7526 is a ligand of Von HippelLindau protein, that can be used for making proteolysis targeting chimeras (PROTACs). |
| CSN27287 | LS-102 | 1456891-34-1 | LS-102 is a selective inhibitor of E3 ubiquitin ligase synoviolin (Syvn1). LS-102 inhibits the autoubiquitination of synoviolin with an IC50 of 35 μM. LS-102 has the potential for rheumatoid arthritis treatment. |
| CSN22273 | 3-(4-(5-Aminopentyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione | 2093388-45-3 | Lenalidomide-C5-Amine is a PROTAC block consist of Lenalidomide linked to alkyl with Amine functional group for conjugation reactions. |
| CSN22267 | E3 Ligand-Linker Conjugate 5 | 2093388-69-1 | Lenalidomide-C4-Amine is a PROTAC block consist of Lenalidomide linked to alkyl with Amine functional group for conjugation reactions. |
| CSN22090 | IACS-9571 | 1800477-30-8 | IACS-9571 is a potent and selective inhibitor of TRIM24 and BRPF1, with IC50 of 8 nM for TRIM24, and Kds of 31 nM and 14 nM for TRIM24 and BRPF1, respectively. |
| CSN22427 | VH032-PEG5-C6-Cl | 1799506-06-1 | HaloPROTAC 2 is a PROTAC block consist of VH032 and a linker with chlorine functional group for conjugation reactions. |
| CSN32744 | MuRF1-IN-1 | 445222-91-3 | EMBL is an inhibitor of MuRF1. |
| CSN28743 | E3 ligase Ligand 9 | 87304-15-2 | E3 ligase Ligand 9 is a Bestatin-based E3 ligase ligand. |
| CSN21237 | (S,R,S)-AHPC TFA | 1631137-51-3 | E3 Ligase Ligand 6 is used for conjugation reactions of PROTAC, which can hijack VHL as the E3 ubiquitin ligase component. |
| CSN21420 | Thalidomide-4-OH | 5054-59-1 | E3 ligase Ligand 2 is a thalidomide derivate for conjugation reactions of PROTAC, which can hijack cereblon as the E3 ubiquitin ligase component. |
| CSN21252 | (S,R,S)-AHPC-Me | 1948273-02-6 | E3 ligase Ligand 1A is a VH032 derivate for conjugation reactions of PROTAC, which can hijack VHL as the E3 ubiquitin ligase component. |
| CSN23876 | COH000 | 1534358-79-6 | COH000 is an irreversible inhibitor of ubiquitin-like 1-activating enzyme (SUMO-activating enzyme) with IC50 of 0.2 μM for SUMOylation in vitro. |
| CSN27230 | Mezigdomide | 2259648-80-9 | CC-92480 is a cereblon E3 ubiquitin ligase modulating drug (CELMoD). CC-92480 shows high affinity to cereblon, resulting in potent antimyeloma activity . |
| CSN22248 | CC-885 | 1010100-07-8 | CC-885 is a cereblon CRBN modulator with potent anti-tumour activity |
| CSN24473 | C25-140 | 1358099-18-9 | C25-140 is an inhibitor of the TRAF6-Ubc13 interaction that reduces TRAF6-Ubc13 activity both in vitro and in cells. |
| CSN64606 | Thalidomide-O-amido-PEG4-C2-NH2 hydrochloride | 2245697-85-0 | |
| CSN28728 | (S,S,S)-AHPC hydrochloride | 2115897-23-7 | |
| CSN33243 | tert-Butyl 4-(2-(2,6-dioxopiperidin-3-yl)-3-oxoisoindolin-5-yl)piperazine-1-carboxylate | 2229723-91-3 | |
| CSN43361 | UbcH5c-IN-1 | 2123480-72-6 | |
| CSN61257 | (2S,4S)-1-((S)-2-Amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide dihydrochloride | 2376990-32-6 | |
| CSN74444 | 4-(((S)-1-((2S,4R)-4-Hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-4-oxobutanoic acid | 2172819-72-4 | |
| CSN74512 | 10-(((S)-1-((2S,4R)-4-Hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-10-oxodecanoic acid | 2172819-77-9 | |
| CSN75632 | EN106 | 757192-67-9 |
+1-708-781-1677
+1-708-286-6026
sales@csnpharm.com
